IPP Bureau
Dr Agarwals Health Care posts consolidated Q2 FY26 PAT at Rs. 29.69 Cr
By IPP Bureau - November 02, 2025
Dr Agarwals Health Care has reported total income of Rs. 506.62 crore during the period ended September 30, 2025
Dabur India reports consolidated Q2 FY26 PAT at Rs. 452.55 Cr
By IPP Bureau - November 02, 2025
Dabur India has reported total income of Rs. 3,331.45 crore during the period ended September 30, 2025
Dr. Agarwals Eye Hospital posts consolidated Q2 FY26 PAT at Rs. 19.32 Cr
By IPP Bureau - November 02, 2025
Dr Agarwals Eye Hospital has reported total income of Rs. 118.40 crore during the period ended September 30, 2025
.jpg "Cipla posts consolidated Q2 FY26 PAT Rs. 1,351.17 Cr")
Cipla posts consolidated Q2 FY26 PAT Rs. 1,351.17 Cr
By IPP Bureau - November 02, 2025
Cipla has reported total income of Rs. 7,858.39 crore during the period ended September 30, 2025
Medanta Super Speciality Hospital to set up new hospital in Guwahati
By IPP Bureau - November 02, 2025
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
Tatva Chintan Pharma Chem reports consolidated Q2 FY26 PAT at Rs. 9.91 Cr
By IPP Bureau - November 02, 2025
Tatva Chintan Pharma Chem has reported total income of Rs. 124.52 crore during the period ended September 30, 2025
Indraprastha Medical Corporation posts consolidated Q2 FY26 PAT at Rs. 49.46 Cr
By IPP Bureau - November 02, 2025
Indraprastha Medical Corporation has reported total income of Rs. 388.40 crore during the period ended September 30, 2025
MedPlus Health Services posts consolidated Q2 FY26 PAT at Rs. 55.50 Cr
By IPP Bureau - November 02, 2025
Medplus Health Services has reported total income of Rs. 1,696.79 crore during the period ended September 30, 2025
Zydus Wellness appoints Manish Lal as Head, Global Demand and Supply Organization
By IPP Bureau - November 02, 2025
With over two decades of extensive experience, Lal has established himself as a transformational leader in the FMCG and consumer goods sectors
Bristol Myers Squibb posts Q3 2025 revenues $12.2 billion
By IPP Bureau - November 02, 2025
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
BMS’ Cobenfy sees steady start, eyes stronger growth ahead
By IPP Bureau - October 31, 2025
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Merck’s Capvaxive shows strong momentum amid industry vaccine decline
By IPP Bureau - October 31, 2025
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success
By IPP Bureau - October 31, 2025
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
